Sandoz’s Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases

 Sandoz’s Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases

Sandoz’s Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases

Shots:

  • The approval is based on the non-inferiority data demonstrating its biosimilarity in terms of PK, immunogenicity and safety meeting all 1Eps & results of ADACCESS study confirming its safety & efficacy with referred biologic
  • Hymiroz’s (a TNFi) approval is third FDA approval for Sandoz which is indicated to treat RA, JIA in patients ≥4 yrs. of age, PsA, AS, adult CD, UC and plaque psoriasis (Ps)
  • On 11 Oct, 2018 Sandoz resolved all global IPR litigations with AbbVie regarding adalimumab biosimilar and is expected for sales on 23 Sep, 2023 in the US

Click here to read full press release/ article | Ref: Sandoz| Image: Vilaggazdasag

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post